MVM LEADS $10.5M FINANCING IN PROVIDENCE MEDICAL

WILSON THERAPEUTICS' WTX101 MEETS PRIMARY ENDPOINT

Wilson Therapeutics AB has announced that the Phase II study of WTX101, an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint

MVM has a global perspective on healthcare and maintains offices in Boston and London. Current MVM portfolio companies are based across the US and Europe as well as in the Middle East and Asia.

Partners of MVM, in aggregate, have more than 110 years of healthcare investment experience and have managed more than 45 healthcare investments. Their backgrounds span medicine, science, operations, finance, private equity, and the public equity markets.